CARA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.7782 USD | +0.78% |
|
+13.72% | +4.74% |
Presenter SpeechMatthew Murphy (Executives)Good morning, and welcome to Cara Therapeutics Capi...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Cara Therapeutics, Inc. is a development-stage biopharmaceutical company. The Company is focused on treatment paradigm to improve the lives of patients suffering from chronic pruritus. It is developing an oral formulation of difelikefalin, a selective, predominantly peripherally acting, non-scheduled Kappa opioid receptor agonist, for the treatment of chronic neuropathic pruritus associated with Notalgia Paresthetica (NP), a common, underdiagnosed neuropathy affecting the upper back. It is conducting Phase II/III Clinical Program in NP. The program is comprised of two studies - KOURAGE 1 and KOURAGE 2, which are double-blind, placebo-controlled, eight-week studies with patients allowed to roll-over into open-label 52-week extensions. It has developed an IV formulation of difelikefalin, for the treatment of moderate-to-severe pruritus associated with advanced chronic kidney disease in adults undergoing hemodialysis. The IV formulation is out-licensed worldwide.
Sector
Pharmaceuticals
Calendar
2024-05-05
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
0.7782
USD
Average target price
5.12
USD
Spread / Average Target
+557.93%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +4.74% | 42.21M | |
| -3.79% | 87.06B | |
| +1.45% | 40.25B | |
| -15.94% | 31.09B | |
| +52.66% | 24.74B | |
| -14.50% | 15.91B | |
| -9.12% | 11.96B | |
| -14.38% | 11.92B | |
| -42.56% | 11.61B | |
| +4.87% | 8.73B |
- Stock Market
- Equities
- CARA Stock
- News Cara Therapeutics, Inc.
- Transcript : Cara Therapeutics, Inc. - Analyst/Investor Day
